212 related articles for article (PubMed ID: 19998512)
1. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor.
Kaemmerer D; Prasad V; Daffner W; Hörsch D; Klöppel G; Hommann M; Baum RP
World J Gastroenterol; 2009 Dec; 15(46):5867-70. PubMed ID: 19998512
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant strategies for advanced pancreatic neuroendocrine tumors: should combined chemotherapy and peptide receptor radionuclide therapy be the preferred regimen for maximizing outcome?
Basu S; Parghane RV; Ostwal V; Shrikhande SV
Nucl Med Commun; 2018 Jan; 39(1):94-95. PubMed ID: 29206780
[No Abstract] [Full Text] [Related]
3. The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.
Raymond LM; Korzun T; Kardosh A; Kolbeck KJ; Pommier R; Mittra ES
Neuroendocrinology; 2021; 111(11):1086-1098. PubMed ID: 33744879
[TBL] [Abstract][Full Text] [Related]
4. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.
Kwekkeboom DJ; Krenning EP
Hematol Oncol Clin North Am; 2016 Feb; 30(1):179-91. PubMed ID: 26614376
[TBL] [Abstract][Full Text] [Related]
5. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms.
Partelli S; Bertani E; Bartolomei M; Perali C; Muffatti F; Grana CM; Schiavo Lena M; Doglioni C; Crippa S; Fazio N; Zamboni G; Falconi M
Surgery; 2018 Apr; 163(4):761-767. PubMed ID: 29284590
[TBL] [Abstract][Full Text] [Related]
6. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
[TBL] [Abstract][Full Text] [Related]
7. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
[TBL] [Abstract][Full Text] [Related]
8. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs).
Sowa-Staszczak A; Pach D; Chrzan R; Trofimiuk M; Stefańska A; Tomaszuk M; Kołodziej M; Mikołajczak R; Pawlak D; Hubalewska-Dydejczyk A
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1669-74. PubMed ID: 21559978
[TBL] [Abstract][Full Text] [Related]
9. Case report of a patient with initially inoperable well-differentiated midgut neuroendocrine tumor (WDNT)--PRRT and long-acting somatostatin analogs as the neoadjuvant therapy.
Sowa-Staszczak A; Pach D; Stefańska A; Szybiński P; Kulig J; Tomaszewska R; Chrzan R; Hubalewska-Dydejczyk A
Nucl Med Rev Cent East Eur; 2012 Aug; 15(2):137-9. PubMed ID: 22936508
[TBL] [Abstract][Full Text] [Related]
10. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
Pach D; Sowa-Staszczak A; Kunikowska J; Królicki L; Trofimiuk M; Stefańska A; Tomaszuk M; Głowa B; Mikołajczak R; Pawlak D; Jabrocka-Hybel A; Hubalewska-Dydejczyk AB
Radiother Oncol; 2012 Jan; 102(1):45-50. PubMed ID: 21885142
[TBL] [Abstract][Full Text] [Related]
11. Successful and Safe Treatment With 177Lu-DOTATATE (Lutathera) of Progressive Metastatic Pancreatic Neuroendocrine Tumor Under Hemodialysis.
Dierickx LO; Séverine B; Fatima M; Amel B; Rosine G
Clin Nucl Med; 2020 Sep; 45(9):e400-e402. PubMed ID: 32701804
[TBL] [Abstract][Full Text] [Related]
12. Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT).
Schiavo Lena M; Partelli S; Castelli P; Andreasi V; Smart CE; Pisa E; Bartolomei M; Bertani E; Zamboni G; Falconi M; Doglioni C
Endocr Pathol; 2020 Jun; 31(2):119-131. PubMed ID: 32361926
[TBL] [Abstract][Full Text] [Related]
13. Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting.
Kalshetty A; Ramaswamy A; Ostwal V; Basu S
Nucl Med Commun; 2018 Dec; 39(12):1143-1149. PubMed ID: 30308585
[TBL] [Abstract][Full Text] [Related]
14. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
15. Peptide Receptor Radionuclide Therapy as First-Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumors.
Satapathy S; Mittal BR; Sood A; Sood A; Kapoor R; Gupta R
Clin Nucl Med; 2020 Sep; 45(9):e393-e399. PubMed ID: 32604121
[TBL] [Abstract][Full Text] [Related]
16. Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy.
Werner RA; Ilhan H; Lehner S; Papp L; Zsótér N; Schatka I; Muegge DO; Javadi MS; Higuchi T; Buck AK; Bartenstein P; Bengel F; Essler M; Lapa C; Bundschuh RA
Mol Imaging Biol; 2019 Jun; 21(3):582-590. PubMed ID: 30014345
[TBL] [Abstract][Full Text] [Related]
17. Metastatic Insulinoma Pancreatic Neuroendocrine Tumor Treated With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy: A Suggested Protocol.
Makis W; McCann K; McEwan AJ
Clin Nucl Med; 2016 Jan; 41(1):53-4. PubMed ID: 26562579
[TBL] [Abstract][Full Text] [Related]
18. Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors.
Ramage J; Naraev BG; Halfdanarson TR
Semin Oncol; 2018 Aug; 45(4):236-248. PubMed ID: 30539715
[No Abstract] [Full Text] [Related]
19. Peptide receptor radionuclide therapy controls inappropriate calcitriol secretion in a pancreatic neuro-endocrine tumor: a case report.
Haemels M; Delaunoit T; Van Laere K; Van Cutsem E; Verslype C; Deroose CM
BMC Gastroenterol; 2020 Oct; 20(1):324. PubMed ID: 33008295
[TBL] [Abstract][Full Text] [Related]
20. The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy.
Yordanova A; Wicharz MM; Mayer K; Brossart P; Gonzalez-Carmona MA; Strassburg CP; Fimmers R; Essler M; Ahmadzadehfar H
Clin Cancer Res; 2018 Oct; 24(19):4672-4679. PubMed ID: 29950352
[No Abstract] [Full Text] [Related]
[Next] [New Search]
